NEW YORK, NY--(Marketwire -01\/31\/12)- Biotechnology stocks have been on a tear this month, gaining an impressive 11 percent. Reuters recently released an article arguing health-care costs are outpacing consumer inflation, leading government and industry to seek ways to cut costs. Reuters' 2012 biotech outlook says this could mean an even greater reliance upon drugs. Five Star Equities examines the outlook for companies in the Biotechnology industry and provides equity research on BioSante Pharmaceuticals Inc. (NASDAQ: BPAX - News) and Cell Therapeutics, Inc. (NASDAQ: CTIC - News). Access to the full company reports can be found at: <\/p>\n
http:\/\/www.fivestarequities.com\/BPAX<\/a> Gunderson Capital Management argues that part of biotech's rally is being driven by expectations that President Barack Obama's health care reform plan may be repealed. Earlier this month House Republicans pushed through a resolution in support of a Constitutional amendment that would repeal Obamacare. House Resolution 1003 asks Congress to call a constitutional convention to propose an amendment to repeal the Affordable Care Act, which is also set to be challenged before the Supreme Court this year. <\/p>\n Five Star Equities releases regular market updates on the biotechnology industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http:\/\/www.fivestarequities.com<\/a> and get exclusive access to our numerous stock reports and industry newsletters. <\/p>\n Cell Therapeutics is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. Earlier this month the company announced that, following discussions with the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP), the CHMP may issue an opinion on CTI's Marketing Authorization Application for Pixuvri in mid-February. Pixantrone is a novel aza-anthracenedione that has distinct structural and physio-chemical properties that make its anti-tumor activity unique in this class of agents. <\/p>\n BioSante Pharmaceuticals, Inc., a specialty pharmaceutical company, develops products for female sexual health and oncology. <\/p>\n Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http:\/\/www.fivestarequities.com\/disclaimer<\/a> <\/p>\n<\/p>\n Read the original here: NEW YORK, NY--(Marketwire -01\/31\/12)- Biotechnology stocks have been on a tear this month, gaining an impressive 11 percent. Reuters recently released an article arguing health-care costs are outpacing consumer inflation, leading government and industry to seek ways to cut costs. Reuters' 2012 biotech outlook says this could mean an even greater reliance upon drugs Continue reading
http:\/\/www.fivestarequities.com\/CTIC<\/a> <\/p>\n
\nShares of BioSante and Cell Therapeutics on the Upswing as Biotech Sector Rallies<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"